Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01464671 · ClinicalTrials.gov registry record · Phase 4
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention
A Phase 4 study, sponsored by Stony Brook University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 260
- Enrollment target
NCT01464671 is a Phase 4 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 260 participants.
The verdict
NCT01464671, a Phase 4 study, was terminated before completion, sponsored by Stony Brook University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 260 participants
- Enrollment target
Study Summary
The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI). The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition, during the index hospitalization and up to 30 days post discharge.
Interventions
- DRUG Heparin
- DRUG Bivalirudin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01464671
The ClinicalTrials.gov registry entry for NCT01464671 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.
NCT01464671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01464671 about?
NCT01464671 is a clinical study titled "Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention". The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI). The primary en...
What is the current status of trial NCT01464671?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2009-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01464671?
The interventions under investigation include: Heparin (DRUG), Bivalirudin (DRUG).
Who is sponsoring clinical trial NCT01464671?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.